Literature DB >> 32079881

A Novel Tripod Percutaneous Reconstruction Technique in Periacetabular Lesions Caused by Metastatic Cancer.

Rui Yang1, Abraham Goch1, Dennis Murphy1, Jichuan Wang1,2, Vanessa Charubhumi1, Jana Fox1, Milan Sen3, Bang Hoang1, David Geller1.   

Abstract

BACKGROUND: Metastatic lesions in the periacetabular region can cause pain and immobility. Symptomatic patients are often treated surgically with a total hip replacement using various modified Harrington methods. These open surgical procedures confer inherent risks. Prolonged recovery and potential complications may delay adjuvant radiation and systemic therapy.
METHODS: We describe a novel technique for acetabular reconstruction. Three large-bore cannulated screws are placed percutaneously under fluoroscopy in a tripod configuration to reinforce the mechanical axes of the acetabulum. Increased stability improves pain control and permits weight-bearing.
RESULTS: Twenty consecutive patients with periacetabular metastases were treated using the tripod technique. Eighteen patients (90%) had Harrington class-III lesions, and 2 patients had Harrington class-II lesions. The mean surgical time was 2.3 hours. Sixteen patients (80%) were able to get out of bed on postoperative day 1. At 3 months postoperatively, there was significant improvement in pain as documented on their visual analog scale (p < 0.01) and in functionality as measured by the Eastern Cooperative Oncology Group score (p < 0.01). The mean follow-up time was 7 months (range, 0.6 to 20 months). At the most recent follow-up, only 3 among the 16 surviving patients were using opioids chronically for pain. Total hip arthroplasty was performed in 4 patients (20%) in a staged fashion using the previously placed screws as support for a cemented cup and obviating the need for a cage device. Of the 16 patients, 15 could walk either independently (6 patients) or using an ambulatory aid (9 patients). Eight patients with the primary tripod reconstruction survived >6 months postoperatively. They were found to have either new bone formation filling the defects or healing of the pathological fractures. There has been no implant loosening or failure.
CONCLUSIONS: The tripod technique is a novel application to provide safe and effective pain relief in the context of periacetabular metastatic disease. It can be easily converted to support a cemented acetabular cup for a total hip replacement should disease progression occur. This technique provides an alternative to open surgery as currently practiced in these patients. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2020        PMID: 32079881     DOI: 10.2106/JBJS.19.00936

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  5 in total

Review 1.  What's new in the management of metastatic bone disease.

Authors:  Shinji Tsukamoto; Costantino Errani; Akira Kido; Andreas F Mavrogenis
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-10-13

2.  Reinforced reconstruction: A technique for the treatment of periacetabular metastases.

Authors:  Gerard Chang; Taylor Paziuk; Tyler Henry; James Krieg; Scot Brown
Journal:  J Orthop       Date:  2021-09-01

Review 3.  Computer-Assisted Surgical Navigation for Primary and Metastatic Bone Malignancy of the Pelvis: Current Evidence and Future Directions.

Authors:  Alexander B Christ; Derek G Hansen; John H Healey; Nicola Fabbri
Journal:  HSS J       Date:  2021-07-07

4.  Augmenting Pathologic Acetabular Bone Loss With Photodynamic Nails to Support Primary Total Hip Arthroplasty.

Authors:  Marilyn Heng; Mitchell S Fourman; Aiden Mitrevski; Emily Berner; Santiago A Lozano-Calderon
Journal:  Arthroplast Today       Date:  2022-10-11

5.  Emerging Concepts in the Surgical Management of Peri-Acetabular Metastatic Bone Disease.

Authors:  Aaron Gazendam; Daniel Axelrod; David Wilson; Michelle Ghert
Journal:  Curr Oncol       Date:  2021-07-17       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.